Inozyme postpones 2025 annual meeting due to pending BioMarin acquisition

Inozyme Pharma, Inc.

Annual Meeting postponed from June 25, 2025 in light of BioMarin (BMRN) acquisition.
If acquisition closes, no public stockholders' meeting will be held.
If acquisition does not close, board will reschedule meeting with a new record date.
Press release issued June 20, 2025; acquisition terms previously announced.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.